Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Rigel Pharmaceuticals, Inc. RIGL
$1.22
+$0.06 (5.17%)
На 18:00, 12 мая 2023
+22.95%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
211873750.00000000
-
week52high
2.22
-
week52low
0.64
-
Revenue
120242000
-
P/E TTM
-3
-
Beta
0.72595100
-
EPS
-0.36000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 июл 2023 г. в 10:59
Описание компании
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 18 авг 2022 г. |
| Piper Sandler | Neutral | Neutral | 17 авг 2022 г. |
| Citigroup | Neutral | Buy | 09 июн 2022 г. |
| B. Riley Securities | Neutral | Neutral | 09 июн 2022 г. |
| BMO Capital | Outperform | Outperform | 09 июн 2022 г. |
| BMO Capital | Outperform | Outperform | 04 ноя 2022 г. |
| Citigroup | Buy | Neutral | 02 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Santos David A | A | 160000 | 160000 | 26 янв 2023 г. |
| Santos David A | A | 100000 | 50000 | 26 янв 2023 г. |
| Santos David A | A | 150000 | 80000 | 26 янв 2023 г. |
| Schorno Dean L | A | 125000 | 125000 | 26 янв 2023 г. |
| Schorno Dean L | A | 100000 | 50000 | 26 янв 2023 г. |
| Schorno Dean L | A | 201908 | 63000 | 26 янв 2023 г. |
| RODRIGUEZ RAUL R | A | 400000 | 200000 | 26 янв 2023 г. |
| Dummer Wolfgang | A | 100000 | 50000 | 26 янв 2023 г. |
| Santos David A | A | 50000 | 50000 | 28 дек 2022 г. |
| Schorno Dean L | A | 50000 | 50000 | 28 дек 2022 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| SPHERA FUNDS MANAGEMENT LTD. | 2162586 | -362414 | 30 сент 2022 г. |
| Vanguard Total Stock Market Index Fund | 4673180 | 0 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 3647720 | 104424 | 31 авг 2020 г. |
| Fidelity Growth Company Fund | 9681450 | -66301 | 31 июл 2020 г. |
| Invesco Oppenheimer Global Opportunities Fund | 5000000 | 0 | 31 июл 2020 г. |
| Vanguard Extended Market Index Fund | 2445710 | -150300 | 31 июл 2020 г. |
| Fidelity Series Growth Company Fund | 2305700 | -121350 | 31 июл 2020 г. |
| Wellington Global Healthcare Equity Fund | 4589840 | 90569 | 30 июн 2020 г. |
| Candriam Equities L Biotechnology | 1943000 | 0 | 30 июн 2020 г. |
| BZ Fine Fund - Pharma | 1780000 | 30000 | 31 мая 2020 г. |
Новостная лента
7 Growth Stocks That Are Too Cheap to Ignore Right Now
InvestorPlace
10 мая 2023 г. в 15:31
Although the equities sector recovered reasonably well from 2022's harsh glare, rising headwinds force consideration of cheap growth stocks to buy now. Essentially, some enterprises with upside potential may be overlooked by other investors, presenting contrarian opportunities.
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
02 мая 2023 г. в 18:23
Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.16 per share a year ago.
Rigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For Profitability
Seeking Alpha
27 апр 2023 г. в 03:27
Rigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For Profitability.
Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update
PRNewsWire
25 апр 2023 г. в 08:05
SOUTH SAN FRANCISCO, Calif. , April 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2023 financial results after market close on Tuesday, May 2, 2023.
4 Top Penny Stocks To Watch With Big Biotech News This Quarter
PennyStocks
08 мар 2023 г. в 10:44
4 biotech penny stocks to watch right now. The post 4 Top Penny Stocks To Watch With Big Biotech News This Quarter appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.